Key Takeaways DGX is set to report Q4 results on Feb. 10, with sales and EPS expected to grow 4.8% and 5.4%, respectively.DGX's DIS business is expected to post strong Q4 growth, aided by physician demand and Fresenius assets. Quest Diagnostics sees Advanced Diagnostics and consumer testing lift Q4, with non-GAAP income up 11.6%. Quest Diagnostics (DGX) is set to release fourth-quarter 2025 results on Feb. 10, before the market opens.The renowned diagnostics provider posted adjusted earnings per share (EPS) ...

New test as sensitive as next-generation sequencing, and provides five-day specimen stability to support nationwide testing In addition to supporting clinical care, the Quest Flow Cytometry MRD for Myeloma test is expected to have utility as a response monitoring tool in clinical trials. In January 2026, the FDA provided draft guidance on using MRD as a primary endpoint in trials evaluating drug and biological products to treat patients with multiple myeloma to support accelerated approval. Quest is a leadi ...

Upgrades - BMO Capital upgraded Southwest (LUV) to Outperform from Market Perform with a price target of $57.50, up from $43, citing significant momentum and earnings upside to at least $4.00 per share in 2026 from 93 cents in 2025 [2] - Barclays upgraded Quest Diagnostics (DGX) to Overweight from Equal Weight with a price target of $210, up from $195, noting sustainable organic growth of 4% from fiscal 2024 to 2025 [3] - Guggenheim upgraded GE Vernova (GEV) to Buy from Neutral with a price target of $910, believing the market may underestimate cash generation potential and margin improvement in the electrification segment [4] - Wolfe Research upgraded Broadcom (AVGO) to Outperform from Peer Perform with a price target of $400, based on channel checks indicating the company will ship 7 million tensor processing units by 2028 [5] - Citi upgraded Spotify (SPOT) to Buy from Neutral with an unchanged price target of $650, stating the stock's valuation is now attractive and consensus estimates are beatable [5] Downgrades - HSBC downgraded Pinterest (PINS) to Hold from Buy with a price target of $24.90, down from $34.50, due to an abrupt jobs cut announcement indicating a softer near-term outlook [6] - Jefferies downgraded Kenvue (KVUE) to Hold from Buy with a price target of $18, down from $23, following shareholder approval for a merger with Kimberly-Clark [6] - Citizens downgraded SAP (SAP) to Market Perform from Outperform without a price target, citing disappointing Q4 sales results and a current cloud backlog growth of 25% versus the expected 26% [6] - D. Boral Capital downgraded Quince Therapeutics (QNCX) to Hold from Buy without a price target after negative results from a pivotal Phase 3 clinical trial [6] - Stifel downgraded Codere Online (CDRO) to Hold from Buy with a price target of $8.50, down from $9, believing the company's estimates need to reset due to a recently announced tax hike in Mexico [6]

Albert Anthony is the pen name of a Croatian-American business author who is a contributing analyst on investor platform & financial media site Seeking Alpha, where he has over +1,000 followers, & also has written for platforms like Investing dot com. He is the author of a new book on Amazon called Real Estate Investment Trusts (REITs): A Fundamental Analysis (2026 Edition).The author's career focus as a business & information systems analyst also included the IT department at top 10 financial firm Charles ...

Fortune's World's Most Admired recognition is based on nine key attributes related to corporate reputation, including quality of products and services, innovation, long-term value and financial profile, social, environmental and community responsibility, and people management. Consulting firm Korn Ferry collaborated with Fortune to survey thousands of executives, directors and analysts who rated companies in their industry, analyzing nearly 700 companies. A company's score must rank in the top half of its i ...

Core Viewpoint - Digi Power X Inc. is actively participating in the PTC 2026 conference to showcase its commitment to developing energy infrastructure that supports next-generation digital workloads, particularly in AI and cloud computing [1][3][4]. Group 1: Company Participation and Strategy - Digi Power X is attending the PTC 2026 in Honolulu, Hawaii, with President Alec Amar representing the company [1]. - The participation reflects the company's strategic focus on scalable, grid-connected energy infrastructure to meet the growing demand for AI-ready data centers and power-intensive computing [3][4]. - Alec Amar emphasized the company's commitment to building the infrastructure for the next era of AI, cloud, and global connectivity, aiming to collaborate with industry leaders [4]. Group 2: Product Development - Digi Power X has initiated the deployment of its ARMS 200 (AI-Ready Modular Solution) platform across select U.S. Tier III facilities, which is designed for full-stack AI infrastructure [5]. - The ARMS 200 platform integrates various components to enable faster and more predictable deployment of AI-ready capacity compared to traditional data center builds [5][6]. - The architecture of ARMS 200 includes grid-connected, multi-megawatt power, modular AI PODs for scalable deployments, high-density GPU racks, and liquid-cooled fabrics optimized for AI workloads [8]. Group 3: Industry Context - The Pacific Telecommunications Council (PTC) serves as a global forum for digital infrastructure, focusing on the convergence of telecommunications and information technology [2]. - The conference addresses critical issues that are shaping the future of industries related to energy, data centers, AI, cloud, and connectivity [2].

"As I've reflected on my years as CEO, I have a blend of emotions — gratitude, pride, and nostalgia," said Dexter. "My fondest memories aren't of milestones reached or metrics made, but of the people with whom I've worked, the resilience during challenges and tough times, and the creativity and innovation that's been brought to every opportunity." Jennifer Erickson succeeds longtime CEO David Dexter following more than 26 years of service PHOENIX, Jan. 15, 2026 /PRNewswire/ -- Sonora Quest Laboratories, tog ...

Core Insights - Quest Diagnostics has tested over 50% of the audience present and tests one-third of the U.S. population annually, indicating its significant market presence and impact on public health [3]. Company Overview - Jim Davis has been the CEO of Quest Diagnostics for three years and has been with the company for 13 years, highlighting his extensive experience and leadership within the organization [2]. - The company emphasizes its mission of creating a healthier world, which has been a consistent message for over a decade, showcasing its long-term commitment to health improvement [3].

Quest Diagnostics FY Conference Summary Company Overview - **Company**: Quest Diagnostics (NYSE: DGX) - **CEO**: Jim Davis - **Industry**: Healthcare Services, specifically laboratory testing Key Points and Arguments Company Position and Market Reach - Quest Diagnostics tests one-third of the U.S. adult population annually, with over 220 million requisitions in 2024, including 80 million blood draws [2][4] - The company operates over 8,000 locations, including 2,000 patient service centers and 6,000 in-office phlebotomists, covering 90% of lives in the U.S. [5] - Quest has a significant presence in Canada and Mexico, with a lab in Mexico and a large laboratory in Canada [6] Revenue and Business Segments - Laboratory testing accounts for about 2% of the $5 trillion U.S. healthcare spend, with the laboratory market valued at approximately $90 billion [7][11] - The revenue breakdown indicates that one-third comes from prevention and wellness testing, while the majority is from chronic disease and sick care testing [7] - The consumer-initiated testing segment has grown from $30 million in 2021 to a projected $250 million, driven by demographic shifts and consumer demand for wellness tests not covered by insurance [23][44] Growth Strategies - Quest is focusing on three growth segments: consumer-initiated testing, support for life sciences companies, and data sales from its extensive patient data points [18] - The company has made significant investments in AI and automation to improve lab efficiency and patient experience [33] - M&A remains a key growth strategy, with $2.8 billion deployed over the last three years, targeting regional independent labs and health system outreach [34] Market Trends and Challenges - The aging population is driving demand for chronic care testing, with individuals aging into Medicare averaging 2.5 chronic conditions [9] - There is a trend of independent physicians joining larger health systems, which may impact the independent lab market [19] - The company anticipates challenges from potential regulatory changes, specifically the PAMA legislation, which could impact revenue by $90-$100 million [41][42] Future Outlook - Quest expects organic revenue growth of 4%-5% for the upcoming year, with operating margin improvements of 75-150 basis points [36][38] - The company is optimistic about the lab market's strength and plans to continue enhancing patient and physician experiences to drive growth [38] - The consumer health segment is expected to grow at a rate of 20% or more, supported by partnerships with wearable technology companies [44] Innovations and Testing Focus - Quest is focusing on advanced testing areas such as cardiometabolic health, autoimmune disorders, brain health (including Alzheimer's testing), and oncology [27][29][31] - The company is developing algorithms to correlate physiological data from wearables with lab biomarkers to enhance personalized health insights [26] Additional Important Information - Quest's operational strategy emphasizes improving the order-to-cash model to enhance patient and physician experiences while reducing costs [31] - The company is leveraging AI for better data management and patient interaction, including future capabilities for patients to chat with their lab results [53] - The overall healthcare system is under strain due to lifestyle changes, necessitating a shift towards preventive care to alleviate costs [46][47]

Market Position and Growth - Quest Diagnostics serves approximately 50% of US hospitals and physicians annually, with around 217 million requisitions expected in 2024[4] - The US lab market is projected to be nearly $90 billion, with Quest holding a 12% market share in the physician channel and a 6% share in the hospital channel[7] - Quest anticipates a long-term revenue growth of 4% to 5% CAGR and adjusted EPS growth of 7% to 9% CAGR beyond 2025[20] - Advanced diagnostic tests in five key clinical areas are expected to generate approximately $1 billion in revenue by 2025[13] - The Canadian lab market is estimated at $5 billion, with LifeLabs holding a 13% market share and strong growth opportunities identified[8] Financial Strategy and Capital Deployment - The company has deployed around $2.8 billion in capital over the last three years for M&A, generating over $1 billion in annual revenue[17] - Quest aims for $4.5 billion to $5.0 billion in operating cash flow and $1.5 billion to $1.7 billion in capital expenditures from 2025 to 2027[19] - Quest's disciplined capital deployment strategy includes approximately $1 billion for dividends and $0.7 billion for share repurchases, aimed at delivering steady annual growth[19] Operational Efficiency and Innovation - Quest's operational strategy includes a 3% annual productivity and cost savings target through continuous improvement initiatives[14] - The company is enhancing customer service and operational efficiency through automation and AI technologies[16]